<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epinephrine (adrenaline) (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epinephrine (adrenaline) (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Epinephrine (adrenaline) (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="105602" href="/d/html/105602.html" rel="external">see "Epinephrine (adrenaline) (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="105605" href="/d/html/105605.html" rel="external">see "Epinephrine (adrenaline) (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45623785"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adrenalin;</li>
<li>Adyphren Amp II [DSC];</li>
<li>Adyphren Amp [DSC];</li>
<li>Adyphren II [DSC];</li>
<li>Adyphren [DSC];</li>
<li>Auvi-Q;</li>
<li>Epinephrine Professional;</li>
<li>EPINEPHrinesnap;</li>
<li>EpinephrineSnap-EMS;</li>
<li>Epinephrinesnap-v;</li>
<li>EpiPen 2-Pak;</li>
<li>EpiPen Jr 2-Pak;</li>
<li>EPIsnap;</li>
<li>Symjepi [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872087"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Adrenalin;</li>
<li>Allerject;</li>
<li>Anapen;</li>
<li>Anapen Junior;</li>
<li>Emerade;</li>
<li>EpiPen;</li>
<li>EpiPen Jr</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F45705702"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Antidote, Hypersensitivity Reactions</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462699"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Epinephrine dosage form concentrations are no longer labeled as ratio expressions (eg, 1:1,000); however, a ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2b2ee979-393f-40d6-abde-d148e1822af0">Cardiopulmonary resuscitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiopulmonary resuscitation</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-33087555','lexi-content-ref-20956432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-33087555','lexi-content-ref-20956432'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">IV, Intraosseous: 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of <b>0.1 mg/mL</b> solution) every 3 to 5 minutes as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Endotracheal: <b>Note:</b> IV route preferred: ET: 0.05 to 0.1 mg/kg (0.5 to 1 mL/kg of <b>0.1 mg/mL</b> solution) every 3 to 5 minutes until IV access established or return of spontaneous circulation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2afa45fc-b843-40a8-8d09-52648fc6e7a7">Hypotension; fluid-refractory/dopamine resistant shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension; fluid-refractory/dopamine resistant shock:</b> Limited data available: Premature and Term neonates: Continuous IV or intraosseous infusion: Initial: 0.02 to 0.1 <b>mcg</b>/kg/<b>minute</b>; usual range: 0.05 to 0.5 <b>mcg</b>/kg/<b>minute</b>; maximum recommended dose: 1 <b>mcg</b>/kg/<b>minute</b>; doses up to 2.6 <b>mcg</b>/kg/<b>minute</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-Domonoske.1','lexi-content-ref-12113327']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-Domonoske.1','lexi-content-ref-12113327'])">Ref</a></span>); optimal approach to dose titration is not established and varies based on clinical scenario (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12113327','lexi-content-ref-15930210','lexi-content-ref-16717120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12113327','lexi-content-ref-15930210','lexi-content-ref-16717120'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F45623833"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Epinephrine dosage form concentrations are no longer labeled as ratio expressions (eg, 1:1,000); however, a ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95337296-2908-46eb-950c-dc9a117b10e5">Asystole or pulseless arrest</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asystole or pulseless arrest</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, Intraosseous (preferred routes of administration): 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) immediately after initiating CPR (within 5 minutes of starting chest compressions), maximum dose: 1 mg/dose; repeat every 3 to 5 minutes until return of spontaneous circulation.</p>
<p style="text-indent:-2em;margin-left:6em;">Endotracheal: 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) immediately after initiating CPR (within 5 minutes of starting chest compressions), maximum dose: 2.5 mg/dose; repeat every 3 to 5 minutes until return of spontaneous circulation or IV/intraosseous access established. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or intraosseous are the preferred methods of administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6254e0b0-d1a0-4413-b531-666b66a5a03e">Bradycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-33081526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-33081526'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV, Intraosseous: 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) (maximum dose: 1 mg/dose or 10 mL/dose); may repeat every 3 to 5 minutes as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Endotracheal: 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) (maximum dose: 2.5 mg/dose); doses as high as 0.2 mg/kg may be effective; may repeat every 3 to 5 minutes as needed until IV/intraosseous access established. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or intraosseous are the preferred methods of administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ca4dc8af-3b83-4d73-872f-78999e01d311">Cardiac output increase or maintenance/post-resuscitation stabilization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac output increase or maintenance/post-resuscitation stabilization: </b>Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 0.05 to 1 <b>mcg</b>/kg/<b>minute</b>; doses &lt;0.3 <b>mcg</b>/kg/<b>minute</b> generally produce beta-adrenergic effects and higher doses (&gt;0.3 <b>mcg</b>/kg/<b>minute</b>) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9d33175-c38e-4c14-8429-b6d533679a19">Hypersensitivity reaction/Anaphylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reaction/Anaphylaxis:</b>
<b>Note:</b> The preferred route of administration is IM administration in the anterolateral aspect of the middle third of the thigh; SUBQ administration results in slower absorption and is less reliable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802','lexi-content-ref-26505932','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802','lexi-content-ref-26505932','lexi-content-ref-21377030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>General dosing or health care settings: </i>IM: 0.01 mg/kg/dose (0.01 mL/kg/dose of <b>1 mg/mL</b> solution) not to exceed: Prepubertal child: 0.3 mg/dose; adolescent: 0.5 mg/dose; administered every 5 to 15 minutes; usual practice is to administer up to 3 doses, but more doses may be needed in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-28193791','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-28193791','lexi-content-ref-21377030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Self-/caregiver-administration following severe allergic reactions (eg, insect stings, food):</i> Autoinjector dose: <b>Note:</b> If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21377030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling (eg, Adrenaclick, Auvi-Q, EpiPen Jr, EpiPen): IM, SUBQ:</p>
<p style="text-indent:-2em;margin-left:10em;">7.5 to &lt;15 kg: 0.1 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.</p>
<p style="text-indent:-2em;margin-left:10em;">15 to &lt;30 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.</p>
<p style="text-indent:-2em;margin-left:10em;">≥30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate dosing: AAP Recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28193791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28193791'])">Ref</a></span>): Limited data available:</p>
<p style="text-indent:-2em;margin-left:10em;">7.5 to &lt;25 kg: 0.15 mg.</p>
<p style="text-indent:-4em;margin-left:12em;">≥25 kg: 0.3 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Refractory cases (unresponsive to IM doses): </i>Continuous IV infusion: Prepared 1 <b>mcg</b>/mL solution: Initial: 0.1 <b>mcg</b>/kg/<b>minute</b>; titrate dose to response. Usual range: 0.1 to 1 <b>mcg</b>/kg/<b>minute</b>; maximum dose: 10 <b>mcg/minute </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802','lexi-content-ref-22211074','lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802','lexi-content-ref-22211074','lexi-content-ref-26505932'])">Ref</a></span>). <b>Note:</b> Suggested concentration of initial solution is more dilute than those typically utilized in other clinical conditions; evaluate infusion concentration with continued therapy and patient fluid status.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c75bd2c4-3b1d-4e1b-b983-93eb5c096819">Hypotension/shock, fluid-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension/shock, fluid-resistant:</b> Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 0.1 to 1 <b>mcg</b>/kg/<b>minute</b>; rates &gt;0.3 <b>mcg</b>/kg/<b>minute</b> associated with vasopressor activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-28509730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-28509730'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7013532e-a761-46fd-ba3c-6e877eddb374">Mydriasis during intraocular surgery, induction, and maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis during intraocular surgery, induction, and maintenance (product specific):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling prior to use.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Intraocular: Must dilute 1 mL of a 1 mg/mL preservative-/sulfite-free, single-use solution to a concentration of 1 <b>mcg</b>/mL to 10 <b>mcg</b>/mL prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 2.5 <b>mcg</b>/mL to 10 <b>mcg</b>/mL dilution.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51108585"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51108586"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F45623834"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="105602" href="/d/html/105602.html" rel="external">see "Epinephrine (adrenaline) (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Epinephrine dosage form concentrations are no longer labeled as ratio expressions (eg, 1:1,000); however, a ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bf96779-1eca-48bc-8c08-ffe899a7920d">Anaphylaxis and other severe immediate hypersensitivity reactions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis and other severe immediate hypersensitivity reactions: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> IM administration in the anterolateral aspect of the middle third of the thigh is preferred; early administration (including before hospital arrival) is essential to prevent progression to life-threatening manifestations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-21377030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 0.3 or 0.5 mg (use 0.5 mg in patients &gt;50 kg unless patient is rapidly deteriorating, then may use 0.3 mg via autoinjector) using the <b>1 mg/mL</b> solution; may repeat every ~5 to 15 minutes (or sooner if clinically indicated) if patient does not adequately respond. Most patients respond to the first or second dose; if inadequate response, additional measures should be instituted (eg, IV fluids and continuous IV epinephrine infusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-Campbell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-Campbell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, intraosseous (alternative routes):</b>
<b>Note: </b>In general, reserve IV administration for patients who are unresponsive (eg, profoundly hypotensive) after several epinephrine IM injections. Only use intraosseous when IV access is not readily available; dosing is the same as IV route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-25466802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-25466802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous infusion (off label):</i>
<b>IV:</b> Initial: 0.1 to 0.2 mcg/<b>kg</b>/minute (or 8 to 16 mcg/minute for an 80 kg patient) administered with fluid resuscitation; starting dose is dependent on severity of anaphylaxis; titrate every 2 to 3 minutes by 0.05 mcg/<b>kg</b>/minute (or 4 mcg/minute) to response; usual dosing range: 0.01 to 0.2 mcg/<b>kg</b>/minute (or ~1 to 16 mcg/minute for an 80 kg patient) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-20956228','lexi-content-ref-14988337','lexi-content-ref-25466802','lexi-content-ref-Campbell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-20956228','lexi-content-ref-14988337','lexi-content-ref-25466802','lexi-content-ref-Campbell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Slow</i>
<i> IV bolus (off label):</i>
<b>Note:</b> Only consider in impending cardiopulmonary arrest when continuous infusion epinephrine is not immediately available; IV bolus administration may be associated with cardiac arrhythmias and cardiac ischemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802','lexi-content-ref-25577622','lexi-content-ref-32595973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802','lexi-content-ref-25577622','lexi-content-ref-32595973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 0.05 to 0.1 mg using the <b>0.1 mg/mL</b> solution (further diluted in 10 mL of NS) administered over 1 to 10 minutes; may repeat once after 3 minutes if patient remains unresponsive to initial dose. If inadequate response, additional measures should be instituted (eg, IV fluids and continuous IV epinephrine infusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-6708262','lexi-content-ref-25466802','lexi-content-ref-Campbell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-6708262','lexi-content-ref-25466802','lexi-content-ref-Campbell.1'])">Ref</a></span>). If patient develops cardiopulmonary arrest, use higher IV/intraosseous bolus doses (ie, 1 mg [using the <b>0.1 mg/mL</b> solution] every 3 to 5 minutes) administered rapidly (see "Sudden Cardiac Arrest due to Asystole, Pulseless Electrical Activity, Ventricular Fibrillation, or Pulseless Ventricular Tachycardia [off-label use]") (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-20956224','lexi-content-ref-25466802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-20956224','lexi-content-ref-25466802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Self-treatment using auto-injector for severe allergic reactions (eg, insect stings, food):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For outpatient use, prescribe at least 2 doses for patients who have a prior anaphylactic reaction and for those at risk for severe anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM (preferred route), SUBQ:</b> 0.3 or 0.5 mg (if available, 0.5 mg dose may be used or prescribed for patients with more severe symptoms or who weigh &gt;60 kg); may repeat every ~5 to 15 minutes (or sooner if clinically indicated) if patient does not adequately respond to initial dose; more than 2 sequential doses should only be administered under direct medical supervision; IM administration is preferred to SUBQ due to more rapid absorption and higher peak concentrations, especially when administered in the thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-20956228','lexi-content-ref-11692118','lexi-content-ref-Bausch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-20956228','lexi-content-ref-11692118','lexi-content-ref-Bausch.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef456e7d-fa37-4f78-a6fa-ee677641f858">Asthma, acute severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute severe (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use in patients who are unable to use inhaled beta-agonists. Although rare and without formal supportive data, may consider in patients who are refractory to standard therapy and are in impending respiratory arrest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222313'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (preferred route), SUBQ:</b> 0.3 to 0.5 mg using the <b>1 mg/mL</b> concentration; if severe symptoms persist after initial dose, may repeat every 20 minutes for a total of 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-Cydulka.1','lexi-content-ref-31443563','lexi-content-ref-32222313','lexi-content-ref-22794687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-Cydulka.1','lexi-content-ref-31443563','lexi-content-ref-32222313','lexi-content-ref-22794687'])">Ref</a></span>). <b>Note:</b> IM administration is preferred to SUBQ due to more rapid absorption and higher peak concentrations when administered in the thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-11692118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-11692118'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18ae4661-ec31-4c3c-83c5-d332e4c822f2">Bradycardia or atrioventricular block, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bradycardia or atrioventricular block, symptomatic (unresponsive to atropine) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV:</b> Initial: 2 to 10 mcg/minute (or 0.025 to 0.125 mcg/<b>kg</b>/minute for an 80 kg patient); usual dosage range: 8 to 40 mcg/minute (or 0.1 to 0.5 mcg/<b>kg</b>/minute for an 80 kg patient); titrate to desired effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e09015f4-003d-4126-9410-366d4a3243fe">Hypotension or shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension or shock:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cardiogenic shock (alternative agent) (off-label use)<b>: </b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<b>Note:</b></b> Typically, not the preferred initial agent in cardiogenic shock; consider other options. Optimal goal of therapy is not well established, but typically titrate to maintain end-organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>). Institutional protocols may vary with weight-based or non-weight-based dose regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV:</b> Usual dosage range: 0.01 to 0.5 mcg/<b>kg</b>/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Non-weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>Usual dosage range: 1 to 40 mcg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28923988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Post–cardiac arrest shock (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Optimal goal of therapy is not well established, but typically titrate to mean arterial blood pressure (MAP) &gt;65 mm Hg and preferably 80 to 100 mm Hg to optimize cerebral and end-organ perfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472996','lexi-content-ref-Rittenberger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472996','lexi-content-ref-Rittenberger.1'])">Ref</a></span>). Institutional protocols may vary with weight-based or non-weight-based dose regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>Usual dosage range: 0.01 to 1 mcg/<b>kg</b>/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); maximum dose for refractory shock: 2 mcg/<b>kg</b>/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-Rittenberger.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-Rittenberger.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Non-weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>Usual dosage range: 1 to 80 mcg/minute; titrate based on clinical end points (eg, MAP, end-organ perfusion); maximum dose for refractory shock: 160 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-Rittenberger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-Rittenberger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Septic shock and other vasodilatory shock states (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Considered as adjunctive use when goal MAP not achieved with initial vasopressor or need for inotropic therapy. In general, maintain goal MAP (eg, ~65 mm Hg); consider use if patient is in shock during or after fluid resuscitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099222','lexi-content-ref-34605781','lexi-content-ref-32049269','lexi-content-ref-9255647','lexi-content-ref-29767636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099222','lexi-content-ref-34605781','lexi-content-ref-32049269','lexi-content-ref-9255647','lexi-content-ref-29767636'])">Ref</a></span>). Institutional protocols may vary with weight-based or non-weight-based dose regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>Initial: 0.01 to 0.2 mcg/<b>kg</b>/minute; titrate to goal MAP or end-organ perfusion; usual dose range: 0.01 to 0.5 mcg/<b>kg</b>/minute; maximum dose range for refractory shock: 0.5 to 2 mcg/<b>kg</b>/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720019','lexi-content-ref-28099222','lexi-content-ref-Manaker.1','lexi-content-ref-18654759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720019','lexi-content-ref-28099222','lexi-content-ref-Manaker.1','lexi-content-ref-18654759'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Non-weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<b>IV: </b>Initial: 1 to 15 mcg/minute; titrate to goal MAP or end-organ perfusion; usual dose range: 1 to 40 mcg/minute; maximum dose range for refractory shock: 40 to 160 mcg/minute (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720019','lexi-content-ref-28099222','lexi-content-ref-Manaker.1','lexi-content-ref-18654759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720019','lexi-content-ref-28099222','lexi-content-ref-Manaker.1','lexi-content-ref-18654759'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69341349-2ce2-472f-af23-cc4f03c9b01e">Inotropic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inotropic support (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Inotropic actions predominate at lower doses and vasoconstrictive actions predominate at higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15343024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15343024'])">Ref</a></span>). Institutional protocols may vary with weight-based or non-weight-based dose regimens.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>Usual dosage range: 0.01 to 0.5 mcg/<b>kg</b>/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-28923988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Non-weight-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>Usual dosage range: 1 to 40 mcg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion) (doses calculated and rounded for an 80 kg patient based on weight-based dosing using the referenced sources) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-28923988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-28923988'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="adbbb847-4442-4ff3-89ef-c958b3e3cc98">Mydriasis during intraocular surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mydriasis (induction and maintenance) during intraocular surgery (product specific):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Must <b>only</b> use preservative-free vials <b>without</b> tartaric acid. Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information for formulation details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2'])">Ref</a></span>). Protocols may vary with concentrations and dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraocular:</b> Prior to use, must dilute 1 mL of a 1 mg/mL single-use solution to a concentration of 1 to 10 <b>mcg</b>/mL or if using for intracameral injection, 2.5 to 10 <b>mcg</b>/mL.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Irrigating solution </i>(using 1 to 10 <b>mcg</b>/mL): Use as needed during the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intracameral injection </i>(using 2.5 to 10 <b>mcg</b>/mL): Injection volume: 0.1 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6966a534-bd84-4341-a53a-713949342867">Sudden cardiac arrest due to asystole, pulseless electrical activity, ventricular fibrillation, or pulseless ventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sudden cardiac arrest due to asystole, pulseless electrical activity, ventricular fibrillation, or pulseless ventricular tachycardia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Intraosseous:</b> 1 mg (using the <b>0.1 mg/mL</b> solution) every 3 to 5 minutes until return of spontaneous circulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31722552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31722552'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Endotracheal (alternative route):</b> 2 to 2.5 mg every 3 to 5 minutes until IV/intraosseous access established or return of spontaneous circulation; before administration, dilute in 5 to 10 mL NS or sterile water (using the <b>1 mg/mL</b> solution) and use hyperventilation or manual ventilation after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-7614276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-7614276'])">Ref</a></span>). <b>Note:</b> May cause false-negative reading with exhaled CO<sub>2</sub> detectors; use second method to confirm tube placement if CO<sub>2</sub> is not detected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991058"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988304"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F45623807"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiomyopathy (stress), cerebrovascular accident, chest pain, hypertension, increased cardiac work, ischemic heart disease, limb ischemia, localized blanching, myocardial infarction, palpitations, peripheral vasoconstriction, supraventricular tachycardia, tachyarrhythmia, tachycardia, vasoconstriction, ventricular arrhythmia, ventricular ectopy, ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Anxiety, apprehension, cerebral hemorrhage, disorientation, dizziness, drowsiness, exacerbation of Parkinson disease, headache, memory impairment, panic, paresthesia, psychomotor agitation, restlessness, tingling sensation</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, gangrene of skin or other tissue (at injection site), pallor, piloerection</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia, hypokalemia, insulin resistance, lactic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Asthenia, tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dyspnea, pulmonary edema, rales</p></div>
<div class="block coi drugH1Div" id="F45623804"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no absolute contraindications to the use of injectable epinephrine (including Adrenaclick, Auvi-Q, EpiPen, EpiPen Jr, Symjepi, Allerject [Canadian product], and Twinject [Canadian product]) in a life-threatening situation. Some products include the following contraindications: Hypersensitivity to sympathomimetic amines; general anesthesia with halogenated hydrocarbons (eg, halothane) or cyclopropane; narrow angle glaucoma; nonanaphylactic shock; in combination with local anesthesia of certain areas such as fingers, toes, and ears; use in situations where vasopressors may be contraindicated (eg, thyrotoxicosis, diabetes, in obstetrics when maternal blood pressure is in excess of 130/80 mm Hg and in hypertension and other cardiovascular disorders).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Injectable solution (Adrenalin, Epinephrine injection, USP): There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F45623805"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: May precipitate or aggravate angina pectoris or induce cardiac arrhythmias; use with caution especially in patients with cardiac disease or those receiving drugs that sensitize the myocardium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Due to peripheral constriction and cardiac stimulation, pulmonary edema may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Due to renal blood vessel constriction, decreased urine output may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, arrhythmias, cerebrovascular disease, coronary artery disease, heart disease, hypertension).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: Correct blood volume depletion before administering any vasopressor.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Use with caution in patients with Parkinson disease; psychomotor agitation or temporary worsening of symptoms may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Use with caution in patients with pheochromocytoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with thyroid disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Lacerations, bent needles, and embedded needles have been reported in young children who are uncooperative during injection for hypersensitivity reaction. To minimize risk, hold the child's leg firmly in place and limit movement prior to and during injection. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible (~3 seconds) (Brown 2016) (also see Administration: IM).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental injection: Accidental injection into digits, hands, or feet may result in local reactions including injection-site pallor, coldness, and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema, or skeletal injury. Patient should seek immediate medical attention if this occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intraocular use: Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information prior to selecting a product. Appropriate products should have an indication for induction and maintenance of mydriasis during intraocular surgery and should not contain any sulfites or preservatives (ISMP 2017). Prior to intraocular use of an appropriate product, must dilute single-use 1 mg/mL (1 mL) solution to a concentration of 1 <b>mcg</b>/mL to 10 <b>mcg</b>/mL. Corneal endothelial damage has occurred when products containing sodium bisulfite have been used undiluted; therefore, dilution is advised prior to any intraocular use. In addition, products containing chlorobutanol must also not be used intraocularly (may be harmful to corneal endothelium).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Some products may contain sulfites as preservatives. The presence of sulfites in some products should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Hypersensitivity reactions: Do not inject into the buttock; may not effectively treat anaphylaxis and has been associated with Clostridial infections (gas gangrene). Serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported rarely at the injection site. Cleansing skin with alcohol may reduce bacteria at the injection site, but alcohol cleansing does not kill <i>Clostridium</i> spores. Preferred injection site is anterolateral aspect of the thigh. Do not administer repeated injections at the same site (tissue necrosis may occur). Monitor for signs/symptoms of injection-site infection.</p></div>
<div class="block foc drugH1Div" id="F45623858"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adyphren Amp: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adyphren Amp II: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adyphren II: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epinephrine Professional: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EPINEPHrinesnap: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EpinephrineSnap-EMS: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epinephrinesnap-v: 1 mg/mL [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EPIsnap: 1 mg/mL [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adyphren: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epinephrinesnap-v: 1 mg/mL [contains edetate (edta) disodium dihydrate, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adrenalin: 30 mg/30 mL (30 mL) [contains chlorobutanol (chlorobutol), disodium edta, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (10 mL); 10 mg/10 mL (10 mL); 30 mg/30 mL (30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adrenalin: 1 mg/mL (1 mL) [contains edetate (edta) disodium dihydrate, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Auvi-Q: 0.1 mg/0.1 mL (2 ea); 0.15 mg/0.15 mL (2 ea); 0.3 mg/0.3 mL (2 ea) [contains sodium bisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EpiPen 2-Pak: 0.3 mg/0.3 mL (1 ea, 2 ea) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EpiPen Jr 2-Pak: 0.15 mg/0.3 mL (2 ea) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.15 mg/0.3 mL (1 ea, 2 ea); 0.15 mg/0.15 mL (1 ea, 2 ea); 0.3 mg/0.3 mL (1 ea, 2 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.15 mg/0.3 mL (1 ea, 2 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symjepi: 0.15 mg/0.3 mL (1 ea [DSC], 2 ea [DSC]); 0.3 mg/0.3 mL (1 ea [DSC], 2 ea [DSC]) [latex free; contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symjepi: 0.15 mg/0.3 mL (1 ea [DSC]); 0.3 mg/0.3 mL (2 ea [DSC]) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F45623789"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F45623860"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (EPINEPHrinesnap Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per each): $148.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (EpinephrineSnap-EMS Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per each): $104.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Epinephrinesnap-v Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per each): $109.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (EPIsnap Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per each): $156.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Adrenalin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $17.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/30 mL (per mL): $10.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (EPINEPHrine (Anaphylaxis) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $17.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/30 mL (per mL): $9.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $10.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (EPINEPHrine PF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $17.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Auvi-Q Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1MG/0.1ML (per each): $373.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.15 mg/0.15 mL (per each): $373.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/0.3 mL (per each): $373.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.15 mg/0.15 mL (per each): $247.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.15 mg/0.3 mL (per each): $187.50 - $346.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/0.3 mL (per each): $187.50 - $346.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (EpiPen 2-Pak Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/0.3 mL (per each): $365.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (EpiPen Jr 2-Pak Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.15 mg/0.3 mL (per each): $365.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (EPINEPHrine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/10 mL (per mL): $1.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (EPINEPHrine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/10 mL (per mL): $1.01 - $1.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872088"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adrenalin: 1 mg/mL (1 mL, 30 mL) [contains chlorobutanol (chlorobutol), sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/10 mL (10 mL); 1 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allerject: 0.15 mg/0.15 mL (1 ea); 0.3 mg/0.3 mL (1 ea) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anapen: 0.3 mg/0.3 mL (0.3 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anapen Junior: 0.15 mg/0.3 mL (0.3 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emerade: 0.5 mg/0.5 mL (1 ea) [contains edetate (edta) disodium, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EpiPen: 0.3 mg/0.3 mL (2 mL) [contains sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EpiPen Jr: 0.15 mg/0.3 mL (2 mL) [contains sodium metabisulfite]</p></div>
<div class="block admp drugH1Div" id="F52614635"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</b></p>
<p style="text-indent:-2em;margin-left:2em;">Endotracheal:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Use <b>0.1 mg/mL</b> solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Use <b>1 mg/mL</b> solution; administer and flush with a minimum of 5 mL NS, followed by 5 manual ventilations.</p>
<p style="text-indent:-2em;margin-left:2em;">Intraocular: Administer as a diluted solution (concentration: 1 to 10 <b>mcg</b>/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult the product labeling prior to use. Appropriate products should have mydriasis during intraocular surgery as an approved indication and should not contain any sulfites or preservatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Direct IV or intraosseous administration: If using <b>0.1 mg/mL</b> concentration, no dilution is necessary; the <b>1 mg/mL</b> concentration must be further diluted.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer as a continuous infusion via an infusion pump. Must be diluted prior to administration. Central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access using a more dilute solution or with a second carrier fluid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-32032273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-32032273'])">Ref</a></span>); frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). <b>Note: </b>Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Avoid use of ankle veins (due to potential for gangrene), leg veins in those suffering from occlusive vascular diseases (eg, diabetic endarteritis, Buerger disease, arteriosclerosis, atherosclerosis).</p>
<p style="text-indent:-2em;margin-left:6em;">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)</p>
<p style="text-indent:-2em;margin-left:6em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote) (see Management of Drug Extravasations for more details). Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM (eg, Auvi-Q, EpiPen, EpiPen Jr): Intramuscularly into anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28193791','lexi-content-ref-18691308','lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28193791','lexi-content-ref-18691308','lexi-content-ref-26505932'])">Ref</a></span>). Administer through clothing if necessary. Before administering to a child, immobilize leg to prevent laceration or other injury and consider restraining children who are likely to move during administration. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21875542','lexi-content-ref-26452720','lexi-content-ref-22594931','lexi-content-ref-21875535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21875542','lexi-content-ref-26452720','lexi-content-ref-22594931','lexi-content-ref-21875535'])">Ref</a></span>). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Some products are single-use products and a new device should be used for each dose; consult product specific labeling. <b>Note:</b> In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arkwright.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arkwright.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Use only <b>1 mg/mL</b> solution. Although not preferred, if used for treatment of anaphylaxis, administer into the anterolateral aspect of the middle third of the thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28193791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28193791'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F45623839"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine solutions for injection can be administered IM, intraosseous, endotracheally, IV, or SUBQ. <b>Note:</b> Adrenaclick, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, and Symjepi contain a single, fixed-dose of epinephrine and may only be administered IM (preferred) or SUBQ. Twinject Auto-Injectors [Canadian product] contain two doses; the first fixed-dose is available for auto-injection; the second dose is available for manual injection following partial disassembly of device.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>IV</b>
<b>:</b> IV infusions require an infusion pump. When administering as a continuous infusion, central line administration is preferred; extravasation may cause severe ischemic necrosis. If central line is not available, may administer for a short duration (&lt;72 hours) through a peripheral IV catheter placed in a large vein, at a proximal site (eg, in or proximal to antecubital fossa). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26014852','lexi-content-ref-34605781','lexi-content-ref-28073314','lexi-content-ref-31698544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26014852','lexi-content-ref-34605781','lexi-content-ref-28073314','lexi-content-ref-31698544'])">Ref</a></span>). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution. Administration through midline catheters may also be an option (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33049486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33049486'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine (or alternative antidote) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">For accidental digital epinephrine injection, inject phentolamine 0.5 to 4.5 mg (diluted in 5 mL NS) divided into multiple SUBQ injections along the area of accidental injury as soon as possible after the injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover the affected areas; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Terbutaline:</p>
<p style="text-indent:-2em;margin-left:10em;">Large extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Small extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> SUBQ administration results in slower absorption and lower peak concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11692118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11692118'])">Ref</a></span>). IM administration is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-21377030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-21377030'])">Ref</a></span>). Administer through clothing if necessary. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21875542','lexi-content-ref-26452720','lexi-content-ref-22594931','lexi-content-ref-21875535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21875542','lexi-content-ref-26452720','lexi-content-ref-22594931','lexi-content-ref-21875535'])">Ref</a></span>). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Adrenaclick, Adrenalin, Allerject [Canadian product], Auvi-Q, EpiPen, EpiPen Jr, Symjepi, and Twinject [Canadian product] should only be injected into the anterolateral aspect of the thigh.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Obesity:</i> For adults with obesity experiencing anaphylaxis, administer recommended dose using a 1.5-inch needle <b>or</b> if patient is rapidly deteriorating, use a fixed-dose autoinjector, if available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Campbell.1','lexi-content-ref-32528643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Campbell.1','lexi-content-ref-32528643'])">Ref</a></span>). In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arkwright.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arkwright.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraocular (product specific):</b> May administer diluted solution (concentration: 1 to 10 <b>mcg</b>/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). <b>Note: </b>Must <b>only</b> use preservative free vials <b>without</b> tartaric acid. Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information. Appropriate products should have mydriasis during intraocular surgery as an approved indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal (cardiac arrest):</b> Dilute in NS or sterile water (using the <b>1 mg/mL</b> epinephrine solution). Absorption may be greater with sterile water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10910841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10910841'])">Ref</a></span>). Stop compressions, spray drug quickly down tube. Follow immediately with several quick insufflations and continue chest compressions. May cause false-negative reading with exhaled CO<sub>2</sub> detectors; use second method to confirm tube placement if CO<sub>2</sub> is not detected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224'])">Ref</a></span>).</p></div>
<div class="block uicn drugH1Div" id="F45623847"><span class="drugH1">Usual Infusion Concentrations: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 10 <b>mcg</b>/mL, 16 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, or 64 <b>mcg</b>/mL </p></div>
<div class="block uicp drugH1Div" id="F45623848"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 16 <b>mcg</b>/mL, 20 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, 40 <b>mcg</b>/mL, or 64 <b>mcg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F45623818"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Epinephrine is sensitive to light and air. Protection from light is recommended. Oxidation turns drug pink, then a brown color. <b>Solutions should not be used if they are discolored or contain a precipitate.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adrenaclick: Store between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze or refrigerate.</p>
<p style="text-indent:-2em;margin-left:4em;">Adrenalin: Store between 20°C to 25°C (68°F to 77°F); do not freeze. Diluted solution for infusion may be stored for up to 4 hours at room temperature or for 24 hours refrigerated.</p>
<p style="text-indent:-2em;margin-left:4em;">Allerject [Canadian product]: Store between 15°C to 30°C (59°F to 86°F); do not refrigerate.</p>
<p style="text-indent:-2em;margin-left:4em;">Auvi-Q: Store between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not refrigerate.</p>
<p style="text-indent:-2em;margin-left:4em;">Epinephrine injection, USP: Store between 20°C to 25°C (68°F to 77°F); do not refrigerate; protect from freezing.</p>
<p style="text-indent:-2em;margin-left:4em;">EpiPen, EpiPen Jr, and Symjepi: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze or refrigerate.</p>
<p style="text-indent:-2em;margin-left:4em;">Twinject [Canadian product]: Store between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze or refrigerate. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53571336"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of type I allergic reactions including anaphylaxis (FDA approved in pediatric patients [age not specified] and adults); induction and maintenance of mydriasis during intraocular surgery (FDA approved in pediatric patients [age not specified] and adults; <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling); treatment of hypotension associated with septic shock (increase mean arterial blood pressure) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Autoinjectors: Emergency treatment (immediate administration) of severe allergic reactions including anaphylaxis in patients at increased risk or previous history of anaphylactic reactions (Auvi-Q: FDA approved in patients weighing ≥7.5 kg; Adrenaclick, EpiPen: FDA approved in patients weighing ≥15 kg); <b>Note:</b> Minimum approved patient weight for some autoinjectors may vary based on product formulation and/or strength (ie, mg dose delivered); consult product specific labeling.</p></div>
<div class="block mst drugH1Div" id="F45623780"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Adrenalin may be confused with Akovaz</p>
<p style="text-indent:-2em;margin-left:4em;">EPINEPHrine may be confused with ePHEDrine</p>
<p style="text-indent:-2em;margin-left:4em;">Epifrin may be confused with ephedrine, EpiPen</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000).</p>
<p style="text-indent:-2em;margin-left:4em;">Epinephrine 1:1000 = 1 mg/mL and is most commonly used IM</p>
<p style="text-indent:-2em;margin-left:4em;">Epinephrine 1:10,000 = 0.1 mg/mL and is used IV</p>
<p style="text-indent:-2em;margin-left:4em;">Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration.</p>
<p style="text-indent:-2em;margin-left:4em;">EpiPen 0.3 mg and EpiPen Jr 0.15 mg auto-injectors, and authorized generic versions, may potentially have delayed injection or be prevented from properly injecting due to device failure from spontaneous activation caused by using sideways force to remove the blue safety release, device failure from inadvertent or spontaneous activation due to a raised blue safety release, difficulty removing the device from the carrier tube, and user errors. Health care providers, patients, and caregivers should periodically review the EpiPen user instructions and practice using the EpiPen trainer to ensure proper understanding and utilization of the EpiPen auto-injector. Patients and caregivers should inspect their epinephrine autoinjector prior to needing it to ensure the blue safety release is not raised and that the device can be easily removed from the carrier tube (FDA 2020).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">EpiPen [US, Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain] and Epigent brand name for gentamicin [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45623814"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of COMT</p></div>
<div class="block dri drugH1Div" id="F45623811"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azosemide: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (with Alpha-Blocking Properties): May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Consider alternatives to this combination and monitor for reduced epinephrine efficacy, and possible paradoxical effects (ie, hypotension), when combined. Use of alternative vasopressor agents (eg, phenylephrine, metaraminol, norepinephrine) is preferred.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: May enhance the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: Avoid epinephrine and consider norepinephrine or phenylephrine when treating hypotension due to promethazine overdose. Consider alternative vasocontrictors in patients treated with promethazine. This combination may be indicated in anaphylaxis treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F45623801"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Epinephrine crosses the placenta (Sandler 1964).</p>
<p style="text-indent:0em;margin-top:2em;">Epinephrine is recommended for the treatment of anaphylaxis in pregnant women. Specific dosing is not available; use with caution and monitor hemodynamic response (Hepner 2013). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (AHA [Jeejeebhoy 2015]).</p></div>
<div class="block mopp drugH1Div" id="F53571337"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">ECG, heart rate, blood pressure, site of infusion for excessive blanching/extravasation, cardiac monitor and blood pressure monitor required during continuous infusion</p></div>
<div class="block pha drugH1Div" id="F45623822"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates alpha-, beta<sub>1</sub>-, and beta<sub>2</sub>-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation (increasing myocardial oxygen consumption), and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta<sub>2</sub>-vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle</p></div>
<div class="block phk drugH1Div" id="F45623824"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Bronchodilation: SUBQ: ~5 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Orally ingested doses are rapidly metabolized in GI tract and liver; pharmacologically active concentrations are not achieved</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Does not cross blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: &lt;5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45855086"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Epipen | Jext</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina Bioquim</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin aguettant | Emerade | Epipen | L-adrenalin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Adrenaline aguettant | Adrenaline jr mylan | Adrenaline mylan | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline (tartrate) aguettant | Adrenaline Parke-Davis | Anahelp | Epipen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin labatec | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Epipen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Epinefrina | Penepin jr</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">ADRENALIN Carino | Adrenalin ethypharm | Adrenalin Infectopharm | Anapen | Emerade | Epipen | Fastjekt | Jext | Min-I-Jet Adrenalin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Epipen</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adrenalini hcl | Epipen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adreject | Adrenalina level | Altellus | Anapen | Emerade</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin aguettant | Adrenalin stragen | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline aguettant | Adrenaline b.braun | Adrenaline cooper | Adrenaline PCH | Anahelp | Anakit | Anapen | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Emerade | Epipen | Ims adrenaline | Jext</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina wzf | Anapen | Emerade | Epipen | Fastjekt | Jext</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Epinephrine minijet</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">EpiPen Jr</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Adrenalini bitartras</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Anapen | Epipen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Epipen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina | Adrenalina Aguettant | Chenpen | Fastjekt | Fastjekt junior</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Epipen | Epiquick</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline aguettant</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jext</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Adrenaline aguettant | Epipen | EpiPen Jr</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Adrenalina wzf | Fastjekt</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline (tartrate) aguettant | Fastjekt | Jext</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Adrenalini | Adrenalini hydrotartras</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Emerade | Epipen | Jext</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin aguettant | Adrenalin stragen | Adrenaline aurum | Emerade | Epipen</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline aguettant | Epipen</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina Aguettant | Adrenalina wzf | Adrenalinum | Fastjekt</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin chloride | Epinephrine | Epipen | Epipen 2-Pak | Epipen jr 2-pak | Symjepi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina | Emerade | Epipen | Spinefe</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina lasca</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Emerade | EpiPen | Penepin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anapen | Epipen</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Epigect</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Epipen | Jext</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin mylan | Adrenalin stragen | Anapen | Emerade | Epipen | EpiPen Jr | Jext</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin aguettant | Epipen</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Epipen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anapen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Penepin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bosmin | Epirenamin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adrenalin | Epipen | Epipen junior</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adrenalina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adrenaline | Adrenotone | Anaguard | Epipen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>“2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2005, 112(24 Suppl): 1-211.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27969574">
<a name="27969574"></a>Adams C, Tucker C, Allen B, et al. Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. <i>J Crit Care</i>. 2017;37:219-223. doi:10.1016/j.jcrc.2016.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/27969574/pubmed" id="27969574" target="_blank">27969574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Adrenaclick (epinephrine) [prescribing information]. McPherson, KS; Hospira, Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Adrenalin (epinephrine) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaleo.1">
<a name="Kaleo.1"></a>Allerject (epinephrine) [Canadian prescribing information]. Richmond, VA: Kaleo, Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed February 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720019">
<a name="17720019"></a>Annane D, Vignon P, Renault A, et al; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. <i>Lancet</i>. 2007;370(9588):676-684. doi:10.1016/S0140-6736(07)61344-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/17720019/pubmed" id="17720019" target="_blank">17720019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arkwright.1">
<a name="Arkwright.1"></a>Arkwright P, Wright N, Bewick D, “Anatomical and Anthropometric Determinants of Intramuscular versus Subcutaneous Administration in Children With Epinephrine Auto-injectors,” <i>J Allergy Clin Immunol</i>, 2013, 131(2):AB199.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaleo.2">
<a name="Kaleo.2"></a>Auvi-Q (epinephrine) [prescribing information]. Richmond, VA: Kaleo Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33087555">
<a name="33087555"></a>Aziz K, Lee CHC, Escobedo MB, et al. Part 5: Neonatal resuscitation 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Pediatrics</i>. 2021;147(Suppl 1):e2020038505E. doi:10.1542/peds.2020-038505E<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/33087555/pubmed" id="33087555" target="_blank">33087555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21875542">
<a name="21875542"></a>Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E. The TEN study: time epinephrine needs to reach muscle. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):235-238. doi: 10.1016/j.anai.2011.06.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/21875542/pubmed" id="21875542" target="_blank">21875542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6708262">
<a name="6708262"></a>Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock. <i>JAMA</i>. 1984;251(16):2118-2122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/6708262/pubmed" id="6708262" target="_blank">6708262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al, “Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,” <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26452720">
<a name="26452720"></a>Brown JC, Tuuri RE, Akhter S, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. <i>Ann Emerg Med</i>. 2016;67(3):307-315.e8. doi: 10.1016/j.annemergmed.2015.07.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26452720/pubmed" id="26452720" target="_blank">26452720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14988337">
<a name="14988337"></a>Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. <i>Emerg Med J</i>. 2004;21(2):149-154. doi:10.1136/emj.2003.009449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/14988337/pubmed" id="14988337" target="_blank">14988337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472996">
<a name="26472996"></a>Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S465-S482. doi:10.1161/CIR.0000000000000262<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26472996/pubmed" id="26472996" target="_blank">26472996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25577622">
<a name="25577622"></a>Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. <i>J Allergy Clin Immunol Pract</i>. 2015;3(1):76-80. doi:10.1016/j.jaip.2014.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/25577622/pubmed" id="25577622" target="_blank">25577622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Campbell.1">
<a name="Campbell.1"></a>Campbell RL, Kelso JM. Anaphylaxis: emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608. doi:10.1016/j.anai.2014.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26014852">
<a name="26014852"></a>Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. <i>J Hosp Med</i>. 2015;10(9):581-585. doi:10.1002/jhm.2394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26014852/pubmed" id="26014852" target="_blank">26014852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cydulka.1">
<a name="Cydulka.1"></a>Cydulka R. Chapter 69. Acute Asthma. In: Tintinalli J, Stapczynski JS, Ma OJ, et al. <i>Tintinalli's Emergency Medicine</i>. 8th ed. New York, NY: McGraw-Hill; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3354935">
<a name="3354935"></a>Cydulka R, Davison R, Grammer L, et al, “The Use of Epinephrine in the Treatment of Older Adult Asthmatics,” <i>Ann Emerg Med</i>, 1988, 17(4):322-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/3354935/pubmed" id="3354935" target="_blank">3354935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.doi: 10.1097/CCM.0000000000002425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davis.1">
<a name="Davis.1"></a>Davis C and Wax P, “Subcutaneous Epinephrine O.D. in a Child Resulting in Dysrhythmias and Myocardial Ischemia,” <i>Vet Hum Toxicol</i>, 1994, 36:367.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7614276">
<a name="7614276"></a>DeBehnke DJ. Endotracheal epinephrine administration. <i>Acad Emerg Med</i>. 1994;1(4):326-327. doi:10.1111/j.1553-2712.1994.tb02637.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/7614276/pubmed" id="7614276" target="_blank">7614276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099222">
<a name="28099222"></a>Dellinger RP, Schorr CA, Levy MM. A users' guide to the 2016 surviving sepsis guidelines. <i>Crit Care Med</i>. 2017;45(3):381-385. doi:10.1097/CCM.0000000000002257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28099222/pubmed" id="28099222" target="_blank">28099222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th edition. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Emerade (epinephrine) [product monograph]. Laval, Quebec, Canada: Bausch Health; June 15, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BPI.1">
<a name="BPI.1"></a>Epinephrine injection [prescribing information]. Freehold, NJ: BPI Labs, LLC; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Belcher.1">
<a name="Belcher.1"></a>Epinephrine Injection [prescribing information]. Lake Forest, IL: Hospira Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lineage.1">
<a name="Lineage.1"></a>Epinephrine injection (auto-injector) [prescribing information]. Lineage Therapeutics Inc.; Horsham, PA: May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>EpiPen/EpiPen Jr (epinephrine) [prescribing information]. St. Louis, MO: Meridian Medical Technologies LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622380">
<a name="33622380"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. <i>Crit Care</i>. 2021;25(1):77. doi:10.1186/s13054-021-03495-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/33622380/pubmed" id="33622380" target="_blank">33622380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>Expert Panel Report 3, “Guidelines for the Diagnosis and Management of Asthma,” <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15987381">
<a name="15987381"></a>Gillies M, Bellomo R, Doolan L, Buxton B. Bench-to-bedside review: inotropic drug therapy after adult cardiac surgery – a systematic literature review. <i>Crit Care</i>. 2005;9(3):266-279. doi:10.1186/cc3024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15987381/pubmed" id="15987381" target="_blank">15987381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12113327">
<a name="12113327"></a>Heckmann M, Trotter A, Pohlandt F, Lindner W. Epinephrine treatment of hypotension in very low birthweight infants. <i>Acta Paediatr</i>. 2002;91(5):566-570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/12113327/pubmed" id="12113327" target="_blank">12113327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24257386">
<a name="24257386"></a>Hepner DL, Castells M, Mouton-Faivre C, Dewachter P. Anaphylaxis in the clinical setting of obstetric anesthesia: a literature review. <i>Anesth Analg</i>. 2013;117(6):1357-1367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/24257386/pubmed" id="24257386" target="_blank">24257386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15343024">
<a name="15343024"></a>Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. <i>Crit Care Med</i>. 2004;32(9):1928-1948. doi:10.1097/01.ccm.0000139761.05492.d6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15343024/pubmed" id="15343024" target="_blank">15343024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S and McMillan M, “Innovative Solutions in Critical Care Units: Extravasation Guidelines,” <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Farewell to ratio expressions on single entity drug labels. <i>Acute Care </i>
<i>ISMP Medication Safety Alert!</i> 2015;20(24):2-3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2">
<a name="ISMP.2"></a>Institute for Safe Medication Practices (ISMP). Mydriasis indication eliminated from Adrenalin brand! <i>Acute Care ISMP Medication Safety Alert</i>. 2017;22(12):1-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.3">
<a name="ISMP.3"></a>Institute for Safe Medication Practices (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956432">
<a name="20956432"></a>Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Pediatrics</i>. 2010;126(5):e1400-1413.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956432/pubmed" id="20956432" target="_blank">20956432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18691308">
<a name="18691308"></a>Kemp SF, Lockey RF, Simons FE, et al, “Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,” <i>Allergy</i>, 2008, 63(8):1061-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/18691308/pubmed" id="18691308" target="_blank">18691308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al, “Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31443563">
<a name="31443563"></a>Kostakou E, Kaniaris E, Filiou E, et al. Acute severe asthma in adolescent and adult patients: current perspectives on assessment and management. <i>J Clin Med</i>. 2019;8(9):1283. doi:10.3390/jcm8091283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/31443563/pubmed" id="31443563" target="_blank">31443563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22594931">
<a name="22594931"></a>Kränke B, Schuster C, Wiednig M, Reiter H. A simple method to improve safety of epinephrine auto-injectors. <i>Pediatr Allergy Immunol</i>. 2012;23(4):399-400. doi: 10.1111/j.1399-3038.2012.01299.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22594931/pubmed" id="22594931" target="_blank">22594931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412710">
<a name="30412710"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):932‐987. doi:10.1016/j.jacc.2018.10.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/30412710/pubmed" id="30412710" target="_blank">30412710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32049269">
<a name="32049269"></a>Lamontagne F, Richards-Belle A, Thomas K, et al; 65 trial investigators. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial. <i>JAMA</i>. 2020;323(10):938-949. doi:10.1001/jama.2020.0930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32049269/pubmed" id="32049269" target="_blank">32049269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9255647">
<a name="9255647"></a>Le Tulzo Y, Seguin P, Gacouin A, et al. Effects of epinephrine on right ventricular function in patients with severe septic shock and right ventricular failure: a preliminary descriptive study. <i>Intensive Care Med</i>. 1997;23(6):664-670. doi:10.1007/s001340050391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/9255647/pubmed" id="9255647" target="_blank">9255647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767636">
<a name="29767636"></a>Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update. <i>Crit Care Med</i>. 2018;46(6):997-1000. doi: 10.1097/CCM.0000000000003119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/29767636/pubmed" id="29767636" target="_blank">29767636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28073314">
<a name="28073314"></a>Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the peripheral administration of vasopressor agents. <i>J Intensive Care Med</i>. 2019;34(1):26-33. doi:10.1177/0885066616686035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28073314/pubmed" id="28073314" target="_blank">28073314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21875535">
<a name="21875535"></a>Lieberman P. The 10-second rule and other myths about epinephrine and autoinjectors. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):189-190. doi: 10.1016/j.anai.2011.07.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/21875535/pubmed" id="21875535" target="_blank">21875535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384. doi:10.1016/j.anai.2015.07.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32222313">
<a name="32222313"></a>Long B, Lentz S, Koyfman A, Gottlieb M. Evaluation and management of the critically ill adult asthmatic in the emergency department setting. <i>Am J Emerg Med</i>. 2020;S0735-6757(20)30171-30176. doi:10.1016/j.ajem.2020.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32222313/pubmed" id="32222313" target="_blank">32222313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manaker.1">
<a name="Manaker.1"></a>Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29110979">
<a name="29110979"></a>Medlej K, Kazzi AA, El Hajj Chehade A, et al. Complications from administration of vasopressors through peripheral venous catheters: an observational study. <i>J Emerg Med</i>. 2018;54(1):47-53. doi:10.1016/j.jemermed.2017.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/29110979/pubmed" id="29110979" target="_blank">29110979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18654759">
<a name="18654759"></a>Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J; CAT Study investigators. A comparison of epinephrine and norepinephrine in critically ill patients. <i>Intensive Care Med</i>. 2008;34(12):2226-2234. doi:10.1007/s00134-008-1219-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/18654759/pubmed" id="18654759" target="_blank">18654759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10910841">
<a name="10910841"></a>Naganobu K, Hasebe Y, Uchiyama Y, et al, “A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,” <i>Anesth Analg</i>, 2000, 91(2):317-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/10910841/pubmed" id="10910841" target="_blank">10910841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEP.1">
<a name="NAEP.1"></a>National Asthma Education and Prevention Program, "Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma," Bethesda, MD, National Institutes of Health, 1997. NIH publication 97-4051.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S729‐S767. doi:10.1161/CIRCULATIONAHA.110.970988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472989">
<a name="26472989"></a>Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18)(suppl 2):S315–S367. doi: 10.1161/CIR.0000000000000252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26472989/pubmed" id="26472989" target="_blank">26472989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31722552">
<a name="31722552"></a>Panchal AR, Berg KM, Hirsch KG, et al. 2019 American Heart Association focused update on advanced cardiovascular life support: use of advanced airways, vasopressors, and extracorporeal cardiopulmonary resuscitation during cardiac arrest: an update to the American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2019;140(24):e881-e894. doi:10.1161/CIR.0000000000000732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/31722552/pubmed" id="31722552" target="_blank">31722552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956225">
<a name="20956225"></a>Peberdy MA, Callaway CW, Neumar RW, et al; American Heart Association. Part 9: post–cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation.</i> 2010;122(18)(suppl 3):S768-S786. doi:10.1161/CIRCULATIONAHA.110.971002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956225/pubmed" id="20956225" target="_blank">20956225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15930210">
<a name="15930210"></a>Pellicer A, Valverde E, Elorza MD, et al. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. <i>Pediatrics</i>. 2005;115(6):1501-1512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15930210/pubmed" id="15930210" target="_blank">15930210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30021076">
<a name="30021076"></a>Perkins GD, Ji C, Deakin CD, et al. A randomized trial of epinephrine in out-of-hospital cardiac arrest. <i>N Engl J Med</i>. 2018;379(8):711-721. doi:10.1056/NEJMoa1806842.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/30021076/pubmed" id="30021076" target="_blank">30021076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33049486">
<a name="33049486"></a>Prasanna N, Yamane D, Haridasa N, Davison D, Sparks A, Hawkins K. Safety and efficacy of vasopressor administration through midline catheters. <i>J Crit Care</i>. 2021;61:1-4. doi:10.1016/j.jcrc.2020.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/33049486/pubmed" id="33049486" target="_blank">33049486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26724290">
<a name="26724290"></a>Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. <i>Am J Crit Care</i>. 2016;25(1):27-32. doi:10.4037/ajcc2016667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26724290/pubmed" id="26724290" target="_blank">26724290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. DOI: 10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28098591">
<a name="28098591"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Crit Care Med</i>. 2017;45(3):486-552. doi:10.1097/CCM.0000000000002255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28098591/pubmed" id="28098591" target="_blank">28098591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rittenberger.1">
<a name="Rittenberger.1"></a>Rittenberger JC, Callaway CW. Post-cardiac arrest management in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 15, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12667275">
<a name="12667275"></a>Rotta AT, Wiryawan B. Respiratory emergencies in children. <i>Respir Care</i>. 2003;48(3):248-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/12667275/pubmed" id="12667275" target="_blank">12667275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23021879">
<a name="23021879"></a>Rudders SA, Geyer BC, Banerji A, Phipatanakul W, Clark S, Camargo CA Jr. Obesity is not a risk factor for repeat epinephrine use in the treatment of anaphylaxis. <i>J Allergy Clin Immunol</i>. 2012;130(5):1216-1218. doi:10.1016/j.jaci.2012.08.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/23021879/pubmed" id="23021879" target="_blank">23021879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18305265">
<a name="18305265"></a>Russell JA, Walley KR, Singer J, et al, “Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock,” <i>N Engl J Med</i>, 2008, 358(9):877-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/18305265/pubmed" id="18305265" target="_blank">18305265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14334587">
<a name="14334587"></a>Sandler M, Ruthren CR, Wood C. Metabolism of C14-norepinephrine and 14-epinephrine and their transmission across the human placenta. <i>Int J Neuropharmacol</i>. 1964;3:123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/14334587/pubmed" id="14334587" target="_blank">14334587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22794687">
<a name="22794687"></a>Shah R, Saltoun CA. Chapter 14: Acute severe asthma (status asthmaticus). <i>Allergy Asthma Proc</i>. 2012;(33)(suppl 1):47-50. doi:10.2500/aap.2012.33.3547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22794687/pubmed" id="22794687" target="_blank">22794687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. <i>J Allergy Clin Immunol</i>. 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28193791">
<a name="28193791"></a>Sicherer SH, Simons FER; Section on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxis. <i>Pediatrics</i>. 2017;139(3). doi: 10.1542/peds.2016-4006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28193791/pubmed" id="28193791" target="_blank">28193791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21377030">
<a name="21377030"></a>Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: summary. <i>J Allergy Clin Immunol</i>. 2011;127(3):587-593. doi:10.1016/j.jaci.2011.01.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/21377030/pubmed" id="21377030" target="_blank">21377030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M2, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015 Oct 28;8(1):32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11692118">
<a name="11692118"></a>Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. <i>J Allergy Clin Immunol</i>. 2001;108(5):871-873. doi:10.1067/mai.2001.119409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/11692118/pubmed" id="11692118" target="_blank">11692118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smetzer.1">
<a name="Smetzer.1"></a>Smetzer J, Cohen M, eds. Mydriasis indication eliminated from Adrenalin brand. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2017;22(12):1-2.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9928712">
<a name="9928712"></a>Stier PA, Bogner MP, Webster K, et al, "Use of Subcutaneous Terbutaline to Reverse Peripheral Ischemia," <i>Am J Emerg Med</i>, 1999, 17(1):91-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/9928712/pubmed" id="9928712" target="_blank">9928712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adamis.1">
<a name="Adamis.1"></a>Symjepi (epinephrine) injection [prescribing information]. San Diego, CA: Adamis Pharmaceuticals Corp; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31698544">
<a name="31698544"></a>Tian DH, Smyth C, Keijzers G, et al. Safety of peripheral administration of vasopressor medications: A systematic review. <i>Emerg Med Australas</i>. 2020;32(2):220-227. doi:10.1111/1742-6723.13406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/31698544/pubmed" id="31698544" target="_blank">31698544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081526">
<a name="33081526"></a>Topjian AA, Raymond TT, Atkins D, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16 Suppl 2):S469-S523. doi:10.1161/CIR.0000000000000901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/33081526/pubmed" id="33081526" target="_blank">33081526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trissel.1">
<a name="Trissel.1"></a>Trissel LA. <i>Handbook on Injectable Drugs</i>. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paladin.1">
<a name="Paladin.1"></a>Twinject (epinephrine) [product monograph]. Montreal, QC: Paladin Labs Inc; December 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-epipen-auto-injector-errors-related-device" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-epipen-auto-injector-errors-related-device</a>. Published March 24, 2020. Accessed March 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27886982">
<a name="27886982"></a>Vadiei N, Daley MJ, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. <i>Ann Pharmacother</i>. 2017;51(3):194-202. doi:10.1177/1060028016682030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/27886982/pubmed" id="27886982" target="_blank">27886982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16717120">
<a name="16717120"></a>Valverde E, Pellicer A, Madero R, Elorza D, Quero J, Cabañas F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. <i>Pediatrics</i>. 2006;117(6):e1213-1222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/16717120/pubmed" id="16717120" target="_blank">16717120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S829-S861. doi:10.1161/CIRCULATIONAHA.110.971069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1734400">
<a name="1734400"></a>Waisman Y, Klein BL, Boenning DA, et al, “Prospective Randomized Double-Blind Study Comparing L-Epinephrine and Racemic Epinephrine Aerosols in the Treatment of Laryngotracheitis (Croup),” <i>Pediatrics</i>, 1992, 89(2):302-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/1734400/pubmed" id="1734400" target="_blank">1734400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32032273">
<a name="32032273"></a>Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. <i>Pediatr Crit Care Med</i>. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32032273/pubmed" id="32032273" target="_blank">32032273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711909">
<a name="14711909"></a>Wenzel V, Krismer AC, Arntz HR, et al, “A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group,” <i>N Engl J Med</i>, 2004, 350(2):105-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/14711909/pubmed" id="14711909" target="_blank">14711909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1447671">
<a name="1447671"></a>Wong AF, McCulloch LM, and Sola A, “Treatment of Peripheral Tissue Ischemia With Topical Nitroglycerin Ointment in Neonates,” <i>J Pediatr</i>, 1992, 121(6):980-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/1447671/pubmed" id="1447671" target="_blank">1447671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization; UNICEF. Department of Maternal, newborn, child and adolescent health. Breastfeeding and maternal medication: recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. World Health Organization. http://www.who.int/maternal_child_adolescent/documents/55732/en/. Published 2002. Accessed August 28, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32528643">
<a name="32528643"></a>Worm M, Nguyen D, Rackley R, et al. Epinephrine delivery via EpiPen Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. <i>Clin Transl Allergy</i>. 2020;10:21. doi:10.1186/s13601-020-00326-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32528643/pubmed" id="32528643" target="_blank">32528643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32595973">
<a name="32595973"></a>Zakka K, Gadi S, Koshlelashvili N, Maleque NM. Acute myocardial injury after administration of intravenous epinephrine for allergic reaction. <i>SAGE Open Med Case Rep</i>. 2020. doi:10.1177/2050313X20933104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/32595973/pubmed" id="32595973" target="_blank">32595973</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105708 Version 410.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
